bluuebunny/crossref_metadata_2025_split huggingface dataset:
Flowslide on a fill slope triggered by a burst water pipe: a case history
Authors: Yan W.M. , Zou Haifeng , Williamson Steven J. , Ho Joe S.Y. , Lee Ryan W.H. , Kong Vince S.F. 
Published: November 2024

This paper presents a case study in Hong Kong of a flowslide occurred on a fill slope triggered by a burst water pipe buried near the slope crest. The onset of failure was recorded by nearby pedestrians and the video was immediately posted in social media, which had caught noticeable public attention. The flowslide resulted in a temporary closure of an undermined road section at the slope crest. The debris travelled over 500 m down the natural hillside within a country park. No casualties were reported. History of the site was studied. Information was collected to establish the chronological order of events happened before the flowslide. Post-landslide investigations including field mapping in the source area and along the debris trail, ground investigations, and a fluid-coupled numerical study were undertaken to examine the probable cause and mechanism of the failure. It is diagnosed that the high mobility of this landslide would be caused by the saturation of a loose fill layer in the slope due to water egress from the burst pipe, which in turn might have triggered a static liquefaction of the loose fill. Lessons learnt from this case history and measures to minimize similar landslide hazard on other fill slopes with similar settings are discussed.
GPR30 Selective Agonist G1 Exhibits Antiobesity Effects and Promotes Insulin Resistance and Gluconeogenesis in Postmenopausal Mice Fed a High‐Fat Diet
Authors: Liu Da , Zheng Mingqi , Lu Congcong , Miao Mengdan , Zhan Yinge , Ma Fangfang , Yin Yajuan , Wei Mei , Wang Wei , Wang Wenyao , Meng Xiangbin , Li Jing , Zhang Yaohua , Liu Gang , Tang Yi-Da 
Published: November 2024

Background: G1, a specific agonist targeting the G protein–coupled receptor 30 (GPR30), has demonstrated significant involvement in combating obesity and regulating glucose homeostasis. Nevertheless, the beneficial effects of G1 treatment have solely been investigated in animal models under normal feeding conditions, leaving its therapeutic potential in high‐fat feeding scenarios unexplored.Material and Methods: To address this gap, our study employed an ovariectomized high‐fat diet mouse model to assess the therapeutic effects of G1 in combating obesity and metabolic dysfunction.Results: The findings revealed that G1 treatment resulted in weight loss, but concurrently led to increased blood glucose levels and insulin resistance. Treatment with G1 resulted in an amplification of fat mobilization and an enhancement of pyruvate carboxylase activity in mice fed a high‐fat diet. Moreover, the combined impact of G1 treatment and a high‐fat diet on pyruvate metabolism, as well as the regulation of crucial gluconeogenesis enzymes such as pyruvate dehydrogenase kinase 4 (PDK4), phosphoenolpyruvate carboxykinase (PEPCK), and glucose transporter 2 (GLUT2), expedites the elevation of blood glucose and the progression of insulin resistance.Conclusions: These findings indicate that G1 treatment is influenced by a high‐fat diet, potentially disrupting glucolipid metabolism and promoting insulin resistance alongside its antiobesity effects. Consequently, further investigation is imperative to thoroughly explore this potential toxic side effect of G1 therapy.
Fluorescence Lifetime Imaging Enables In Vivo Quantification of PD-L1 Expression and Intertumoral Heterogeneity
Authors: Pal Rahul , Krishnamoorthy Murali , Matsui Aya , Kang Homan , Morita Satoru , Taniguchi Hajime , Kobayashi Tatsuya , Morita Atsuyo , Choi Hak Soo , Duda Dan G. , Kumar Anand T. N. 
Published: November 2024

Abstract
Patient selection for cancer immunotherapy requires precise, quantitative readouts of biomarker expression in intact tumors that can be reliably compared across multiple subjects over time. The current clinical standard biomarker for assessing immunotherapy response is PD-L1 expression, typically quantified using IHC. This method, however, only provides snapshots of PD-L1 expression status in microscopic regions of ex vivo specimens. Although various targeted probes have been investigated for in vivo imaging of PD-L1, nonspecific probe accumulation within the tumor microenvironment has hindered accurate quantification, limiting the utility for preclinical and clinical studies. Here, we demonstrated that in vivo time-domain fluorescence imaging of an anti–PD-L1 antibody tagged with the near-infrared fluorophore IRDye 800CW (αPDL1-800) can yield quantitative estimates of baseline tumor PD-L1 heterogeneity across untreated mice, as well as variations in PD-L1 expression in mice undergoing clinically relevant anti–PD-1 treatment. The fluorescence lifetime (FLT) of PD-L1–bound αPDL1-800 was significantly longer than the FLT of nonspecifically accumulated αPDL1-800 in the tumor microenvironment. This FLT contrast allowed quantification of PD-L1 expression across mice both in superficial breast tumors using planar FLT imaging and in deep-seated liver tumors (&gt;5 mm depth) using the asymptotic time-domain algorithm for fluorescence tomography. These findings suggest that FLT imaging can accelerate the preclinical investigation and clinical translation of new immunotherapy treatments by enabling robust quantification of receptor expression across subjects.
Significance: Fluorescence lifetime imaging can quantify PD-L1 expression across multiple mice undergoing anti–PD-1 treatment, providing a critically needed noninvasive imaging method to quantify immunotherapy targets in vivo.
Modeling Drug Responses and Evolutionary Dynamics Using Patient-Derived Xenografts Reveals Precision Medicine Strategies for Triple-Negative Breast Cancer
Authors: Shea Abigail , Eyal-Lubling Yaniv , Guerrero-Romero Daniel , Manzano Garcia Raquel , Greenwood Wendy , O’Reilly Martin , Georgopoulou Dimitra , Callari Maurizio , Lerda Giulia , Wix Sophia , Giovannetti Agnese , Masina Riccardo , Esmaeilishirazifard Elham , Cope Wei , Martin Alistair G. , Nagano Ai , Young Lisa , Kupczak Steven , Cheng Yi , Bardwell Helen , Provenzano Elena , Kane Justine , Lay Jonny , Grybowicz Louise , McAdam Karen , Caldas Carlos , Abraham Jean , Rueda Oscar M. , Bruna Alejandra 
Published: November 2024

Abstract
The intertumor and intratumor heterogeneity of triple-negative breast cancers, which is reflected in diverse drug responses, interplays with tumor evolution. In this study, we developed a preclinical experimental and analytical framework using patient-derived tumor xenografts (PDTX) from patients with treatment-naïve triple-negative breast cancers to test their predictive value in personalized cancer treatment approaches. Patients and their matched PDTXs exhibited concordant drug responses to neoadjuvant therapy using two trial designs and dosing schedules. This platform enabled analysis of nongenetic mechanisms involved in relapse dynamics. Treatment resulted in permanent phenotypic changes, with functional and therapeutic consequences. High-throughput drug screening methods in ex vivo PDTX cells revealed patient-specific drug response changes dependent on first-line therapy. This was validated in vivo, as exemplified by a change in olaparib sensitivity in tumors previously treated with clinically relevant cycles of standard-of-care chemotherapy. In summary, PDTXs provide a robust tool to test patient drug responses and therapeutic regimens and to model evolutionary trajectories. However, high intermodel variability and permanent nongenomic transcriptional changes constrain their use for personalized cancer therapy. This work highlights important considerations associated with preclinical drug response modeling and potential uses of the platform to identify efficacious and preferential sequential therapeutic regimens.
Significance: Patient-derived tumor xenografts from treatment-naïve breast cancer samples can predict patient drug responses and model treatment-induced phenotypic and functional evolution, making them valuable preclinical tools.
Small Area Estimation of PSA Testing in US States and Counties
Authors: Liu Benmei , Pleis John R. , Khan Diba , Parsons Van L. , Lee Richard , Cai Bill , Town Machell , Feuer Eric J. , He Yulei 
Published: November 2024

Abstract

Background:
In 2012, the US Preventive Services Task Force recommended against prostate cancer screening using the PSA test for all age groups. In 2018, the US Preventive Services Task Force’s recommendation shifted from a “D” (not recommended) to a “C” (selectively offering PSA-based screening based on professional judgment and patient preferences) in men ages 55 to 69. Limited reliable county-level prostate cancer screening data are available for cancer surveillance purposes.

Methods:
Utilizing data from the National Health Interview Survey (NHIS) and Behavioral Risk Factor Surveillance System (BRFSS) collected in 2012 to 2019, state- and county-level small area models were developed for estimating PSA testing. Model diagnosis, internal validation, and external validation examining associations of PSA testing and prostate cancer incidence were conducted.

Results:
Model-based estimates of PSA testing rates were produced for all US states and 3,142 counties for two data periods: 2012 to 2016 and 2018 to 2019. Geographic variations across counties were demonstrated through maps. Moderate positive correlations between PSA-based screening and prostate cancer incidence were observed, e.g., the state-level weighted Pearson’s correlation coefficients were 0.5025 (P value = 0.0002) and 0.3691 (P value = 0.0077) for 2012 to 2016 and 2018 to 2019, respectively.

Conclusions:
These modeled estimates showed improved precision and adjusted for the differences between the BRFSS and NHIS. The approach of combining the NHIS and BRFSS utilized strengths of the larger sample size of the BRFSS and generally higher response rates and better household coverage from the NHIS.

Impact:
The resulting small area estimates offer a valuable resource for the cancer surveillance community, aiding in targeted interventions, decision making, and further research endeavors.
Targeting c-MET for Endoscopic Detection of Dysplastic Lesions within Barrett’s Esophagus Using EMI-137 Fluorescence Imaging
Authors: Huang Yi-Jhih , Rieder Jonas , Tan Kel Vin , Tenditnaya Anna , Vojnovic Borivoj , Gorpas Dimitris , Quante Michael , Vallis Katherine A. 
Published: November 2024

Abstract

Purpose:
Esophageal cancer carries a poor prognosis with a 5-year overall survival of less than 20%. Barrett’s esophagus increases the risk of esophageal adenocarcinoma. The aim of this study was to investigate the ability of EMI-137, a mesenchymal–epithelial transition factor (c-MET)-targeting optical imaging tracer, to detect dysplasia in Barrett’s esophagus.

Experimental Design:
c-MET expression in human esophageal tissue was investigated using Gene Expression Omnibus datasets, tissue microarrays, and Barrett’s esophagus biopsies. EMI-137 was tested in a dual xenograft mouse model bearing OE33 (c-MET high expression) and FLO-1 (c-MET low expression) tumors. Fluorescence molecular endoscopy was performed in a mouse model of Barrett’s-like metaplasia and dysplasia (L2-IL1β). Tumors and organs of interest were evaluated through ex vivo fluorescence imaging.

Results:
MET mRNA expression analyses and c-MET immunostaining confirmed upregulation of c-MET in Barrett’s esophagus and esophageal adenocarcinoma compared with normal epithelium. There was strong accumulation of EMI-137 in OE33 xenografts 3 hours after injection, decreasing by more than 50% on coinjection of a 10-fold molar excess of unlabeled EMI-137. The target-to-background ratio at 3 hours after injection for OE33 and FLO-1 tumors was 10.08 and 1.42, respectively. Fluorescence molecular endoscopy of L2-IL1β mice showed uptake of EMI-137 in dysplastic lesions within Barrett’s esophagus with a target-to-background ratio of 1.9 in vivo and greater than 2 in ex vivo fluorescence imaging.

Conclusions:
EMI-137 accumulates in dysplastic lesions within Barrett’s esophagus and also in c-MET–positive esophageal adenocarcinoma. EMI-137 imaging has potential as a screening and surveillance tool for patients with Barrett’s esophagus and as a means to detecting dysplasia and esophageal adenocarcinoma.
Pathogenic Variants in Cancer Susceptibility Genes Predispose to Ductal Carcinoma In Situ of the Breast
Authors: Huang Huaizhi , Couch Ronan E. , Karam Rachid , Hu Chunling , Boddicker Nicholas , Polley Eric C. , Na Jie , Ambrosone Christine B. , Yao Song , Trentham-Dietz Amy , Eliassen A. Heather , Penney Kathryn , Brantley Kristen , Bodelon Clara , Teras Lauren R. , Hodge James , Patel Alpa , Haiman Christopher A. , John Esther M. , Neuhausen Susan L. , Martinez Elena , Lacey James V. , O’Brien Katie M. , Sandler Dale P. , Weinberg Clarice R. , Palmer Julie R. , Bertrand Kimberly A. , Vachon Celine M. , Olson Janet E. , Ruddy Kathryn E. , Anton-Culver Hoda , Ziogas Argyrios , Goldgar David E. , Nathanson Katherine L. , Domchek Susan M. , Weitzel Jeffrey N. , Kraft Peter , Dolinsky Jill S. , Pesaran Tina , Richardson Marcy E. , Yadav Siddhartha , Couch Fergus J. 
Published: November 2024

Abstract

Purpose:
To determine the relationship between germline pathogenic variants (PV) in cancer predisposition genes and the risk of ductal carcinoma in situ (DCIS).

Experimental Design:
Germline PV frequencies in breast cancer predisposition genes (ATM, BARD1, BRCA1, BRCA2, CDH1, CHEK2, PALB2, RAD51C, and RAD51D) were compared between DCIS cases and unaffected controls and between DCIS and invasive ductal breast cancer (IDC) cases from a clinical testing cohort (n = 9,887), a population-based cohort (n = 3,876), and the UK Biobank (n = 2,421). The risk of contralateral breast cancer (CBC) for DCIS cases with PV was estimated in the population-based cohort.

Results:
Germline PV were observed in 6.5% and 4.6% of women with DCIS in the clinical testing and population-based cohorts, respectively. BRCA1, BRCA2, and PALB2 PV frequencies were significantly lower among women with DCIS than those with IDC (clinical cohort: 2.8% vs. 5.7%; population-based cohort: 1.7% vs. 3.7%), whereas the PV frequencies for ATM and CHEK2 were similar. ATM, BRCA1, BRCA2, CHEK2, and PALB2 PV were significantly associated with an increased risk of DCIS (OR &gt; 2.0), but only BRCA2 PV were associated with high risk (OR &gt; 4) in both cohorts. The cumulative incidence of CBC among carriers of PV in high-penetrance genes with DCIS was 23% over 15 years.

Conclusions:
The enrichment of PV in ATM, BRCA1, BRCA2, CHEK2, and PALB2 among women with DCIS suggests that multigene panel testing may be appropriate for women with DCIS. Elevated risks of CBC in carriers of PV in high-penetrance genes with DCIS confirmed the utility of testing for surgical decision-making.
Impact of the February 6, 2023, Turkey earthquake on post-traumatic stress disorder, internet addiction and insomnia: A cross-sectional study
Authors: Sehlikoğlu Şeyma , Bekircan Esra , Gündüz Abdülkadir 
Published: November 2024

Background: After earthquakes, individuals may increase their internet usage to cope with post-traumatic stress symptoms, potentially leading to internet addiction and sleep disturbances. Aims: This study aims to determine the levels of post-traumatic stress disorder (PTSD), internet addiction and insomnia in earthquake survivors 1 year after the event and to explore the relationships between these variables. Methods: This cross-sectional descriptive study was conducted between April and June 2024 through face-to-face interviews with 554 individuals who survived the February 6, 2023 earthquake in Turkey, 1 year after the event. Data were collected using the PTSD Checklist for DSM-5 (PCL-5), the Young Internet Addiction Test-Short Form (YIAT-SF) and the Insomnia Severity Index (ISI). Results: A statistically significant moderate positive correlation was found between PCL-5, YIAT-SF and ISI based on the Pearson correlation test ( r = .32 and .44, respectively; p < .05). According to the logistic regression analysis, experiencing physical injury during the earthquake and the loss of first-degree relatives were found to predict the severity of PTSD symptoms ( p = .04, OR = 2.44, 95% CI [1.04, 5.65]; p < .001, OR = 1.98, 95% CI [1.26, 3.06], respectively). Additionally, the YIAT-SF and ISI variables were found to be statistically significant predictors of PTSD symptom severity ( p < .001, OR = 1.04, 95% CI [1.01, 1.07]; p < .001, OR = 1.18, 95% CI [1.12, 1.23], respectively). Conclusions: It is concluded that the severity of PTSD symptoms in earthquake survivors is associated with the severity levels of insomnia and internet addiction. Additionally, it is determined that experiencing injury or loss of a loved one during the earthquake may increase the severity of PTSD symptoms. To protect earthquake survivors from the risk of PTSD, it may be necessary to provide psychosocial support focussed on positive coping strategies for internet addiction and insomnia.
Examining the Relationship Between Positive Thinking Skills and Patience Tendency in Women
Authors: Özbay Ahmet , Demirci Seyrek Özgür , Söylemez Naciye Ece 
Published: November 2024

This study investigates the relationship between positive thinking skills and patience tendencies among women in Istanbul, Turkey. A sample of 405 female participants with an average age of 32 years completed measures of positive thinking and patience. Results revealed a significant positive correlation between positive thinking and overall patience tendency, as well as its sub-dimensions (short-term, long-term, and interpersonal patience). Furthermore, positive thinking was found to be a significant predictor of patience disposition. These findings suggest that positive thinking may serve as a valuable resource for enhancing women’s patience tendencies, potentially contributing to improved life quality and resilience. This study highlights the interconnected nature of these psychological traits and their potential importance in women’s psychological well-being.
High Systemic Immune-Inflammation Index Values Before Treatment Predict Poor Pancreatic Cancer Outcomes After Definitive Chemoradiotherapy
Authors: Topkan Erkan , Kucuk Ahmet , Ozturk Duriye , Ozkan Emine Elif , Kılıç Durankuş Nilüfer , Şenyürek Şükran , Selek Ugur , Pehlivan Berrin 
Published: November 2024

Background: The systemic immune-inflammation index (SII) is an effective tool for predicting the prognosis of patients with cancer. However, its value in patients with locally advanced pancreatic ductal adenocarcinoma (LA-PDAC) undergoing definitive chemoradiotherapy has yet to be addressed. Therefore, we aimed to retrospectively investigate the prognostic significance of the pretreatment SII on the survival outcomes of patients with unresectable LA-PDAC treated with concurrent chemoradiotherapy (C-CRT). Methods: The study included 163 patients with LA-PDAC who had received C-CRT. Using receiver operating characteristic (ROC) curve analysis, the utility of a pre-C-CRT cutoff that could stratify survival results was investigated. The primary and secondary endpoints were the correlations between SII levels and overall survival (OS) and progression-free survival (PFS). Results: At a median follow-up period of 15 months (range: 3.2-94.5), the median OS and PFS rates for the entire group were 15.7 months (95% confidence interval [CI]: 13.4-17.9), and 7.8 months (95% CI: 6.1-9.4), respectively. We divided the patients into 2 SII cohorts based on the ROC curve analysis (area under the curve [AUC]: 71.9%; sensitivity: 68.9%; specificity: 66.7%): SII < 538 (N = 70) and SII ⩾ 538 (N = 93). Comparative survival analysis showed significantly inferior median OS (13.0 vs 25.4 months; P < .001) and PFS (7.0 vs 15.2 months; P = .003) in patients with SII ⩾ 538 compared with those with SII < 538 before treatment. In multivariate analyses, the Eastern Cooperative Oncology Group (ECOG) performance of 2, N1-2 lymph node, CA 19-9 > 90 U/mL, and SII ⩾ 538 status emerged as independent prognosticators of inferior OS and PFS. Conclusions: Present results indicate that patients with unresectable LA-PDAC who underwent C-CRT and had a pretreatment SII ⩾ 538 had significantly worse OS and PFS outcomes compared with those with lower SII values.
Adolescent Perspectives on a School-Based Mind-Body Intervention
Authors: Pike Julie M. , Panoch Janet E. , Haberlin-Pittz Kathryn M. , Hannon Tamara S. 
Published: November 2024

Background Poor mental health among adolescents increased over the last decade prompting recommendations for school-based primary prevention programs that promote mental health. Mind-body modalities offer an evidence-based approach to support well-being, however few studies have evaluated the adolescent experience of participating in these groups. Objective To engage high school students in a mind-body skills group (MBSG) to assess acceptability in an afterschool setting, learn about the adolescent experience of participating in a MBSG, and get recommendations to enhance program acceptability. To collect preliminary data on mindfulness, social support, emotional regulation, and quality of life. Methods Ten high school students participated in an afterschool MBSG. A focus group was conducted 1-week post-intervention. Surveys were administered at baseline, 1-week post-intervention (T1), and 10-weeks post-intervention (T2). The research team used qualitative thematic analysis with inductive and thematic coding. Descriptive statistics of survey scores were calculated, but the study was not powered to detect statistical significance. Results Participants deemed the group to be acceptable. They valued the sense of community derived from the group and enjoyed learning a variety of mind-body skills. Participants recommended adaptations to build connections sooner within the group, offer more interactive experiences with mind-body skills, and prioritize social, emotional, and physical comfort. Mindfulness, emotional regulation, and quality of life scores increased from baseline to T1. All survey scores improved from baseline to T2. Conclusion This study offers insights into the adolescent experience and recommendations for program adaptations for a MBSG in an afterschool setting. Understanding the adolescent perspective is essential for the development of an acceptable MBSG, which has implications for program implementation, utilization, and effectiveness.